Ming Chu
Impact in
- Infectious Diseases top 10%
- HIV/AIDS drug development and treatment
- Pharmacology top 5%
- Berberine and alkaloids research
Papers in
- Oncology 33
- Pancreatic and Hepatic Oncology Research 10
- Cancer-related Molecular Pathways 6
- Colorectal Cancer Treatments and Studies 4
-
- Biochemical and Molecular Research 16
- Co-authors
- G.A. Fischer (3 shared papers)Zheng-yun Chu (7 shared papers)Yuedan Wang (13 shared papers)Glenn A. Fischer (2 shared papers)Mingbo Zhang (3 shared papers)Richard L. Momparler (1 shared paper)Yimiao Zhu (1 shared paper)Zhou Zhou (1 shared paper)
- Journals
- Biochemical Pharmacology (7 papers)Frontiers in Pharmacology (6 papers)PLoS ONE (4 papers)Frontiers in Immunology (3 papers)Pharmacology (3 papers)
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Ming Chu
96 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 130
- Infectious Diseases 259
- Pharmacology 121
- Molecular Biology 959
- Physiology 63
- Oncology 338
Countries citing papers authored by Ming Chu
This map shows the geographic impact of Ming Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Chu more than expected).
Fields of papers citing papers by Ming Chu
This network shows the impact of papers produced by Ming Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Chu. The network helps show where Ming Chu may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1962 | 258 | |
| 2 | 1965 | 187 | |
| 3 | 2016 | 106 | |
| 4 | 2014 | 89 | |
| 5 | 1968 | 86 | |
| 6 | 2017 | 86 | |
| 7 | 2015 | 74 | |
| 8 | 2022 | 67 | |
| 9 | Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. | 1984 | 65 |
| 10 | 1977 | 50 | |
| 11 | 1978 | 47 | |
| 12 | 2015 | 45 | |
| 13 | 1977 | 38 | |
| 14 | 1980 | 38 | |
| 15 | 2014 | 38 | |
| 16 | 1984 | 37 | |
| 17 | Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. | 1998 | 35 |
| 18 | 2018 | 34 | |
| 19 | 2018 | 31 | |
| 20 | 2022 | 30 |
About Ming Chu
Ming Chu is a scholar working on Oncology, Molecular Biology, Immunology, Infectious Diseases and Surgery, having authored 102 papers that have together received 2.1k indexed citations. Recurring topics across this work include Biochemical and Molecular Research (16 papers), Pancreatic and Hepatic Oncology Research (10 papers), Cancer-related Molecular Pathways (6 papers), Berberine and alkaloids research (6 papers), HIV/AIDS drug development and treatment (5 papers), Pancreatitis Pathology and Treatment (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Infectious Diseases (259 citations), Pharmacology (121 citations), Molecular Biology (959 citations), Physiology (63 citations) and Oncology (338 citations). Ming Chu has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include G.A. Fischer, Zheng-yun Chu, Yuedan Wang, Glenn A. Fischer, Mingbo Zhang, Richard L. Momparler, Yimiao Zhu, Zhou Zhou, Ran Ding and Paul Calabresi. Their work appears in journals such as Biochemical Pharmacology, Frontiers in Pharmacology, PLoS ONE, Frontiers in Immunology and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.